title: miR-150 is a factor of survival in prostate cancer patients.
abstract: OBJECTIVE
  Prostate cancer (PC) is the most common malignant disease in males and the second leading cause of cancer related deaths in men in developed countries. The purpose of this study was to investigate whether microRNA (miR)-150 is a factor influencing survival in prostate cancer patients.
  
  
  METHODS
  miR-150 mRNA and protein expression levels in prostatic cancer cell lines and healthy tissues were determined by quantitative (q) RT-PCR and Western blotting. Additionally, the protein expression of miR-150 was detected by immunohistochemistry.
  
  
  RESULTS
  High miR-150 expression was positively correlated with tumor recurrence or metastasis (p=0.010). In addition, PC patients with high miR-150 expression had significantly poorer overall survival/OR (hazard ratio/HR, 1.87; 95% confidence interval/CI, 1.19-2.94; p=0.006) and poorer disease-free survival/DFS (HR, 1.90; 95% CI, 1.21- 2.98; p=0.005) than those with low miR-150 expression. The cumulative 5-year OS was only 35.19% (95% CI, 26.18- 44.20) in the high miR-150 expression group, whereas it was 55.93% (95% CI, 43.26-68.60) in the low miR-150 expression group (p<0.05). Multivariate Cox regression analysis demonstrated that the expression of miR-150, tumor size, and number of tumor lesions were independent prognostic predictors for OS in PC patients.
  
  
  CONCLUSIONS
  miR-150 was overexpressed in PC at both the mRNA and protein levels, and high expression of miR-150 could serve as a novel and reliable prognostic biomarker for PC patients.
authors.affiliation: Department of Urology, Second Artillery General Hospital of PLA, Beijing, China.
authors.forename: Liu
authors.initials: L
authors.lastname: Dezhong
authors.forename: Zhang
authors.initials: Z
authors.lastname: Xiaoyi
authors.forename: Long
authors.initials: L
authors.lastname: Xianlian
authors.forename: Zhang
authors.initials: Z
authors.lastname: Hongyan
authors.forename: Zhao
authors.initials: Z
authors.lastname: Guohua
authors.forename: Sun
authors.initials: S
authors.lastname: Bo
authors.forename: Zou
authors.initials: Z
authors.lastname: Shenglei
authors.forename: Zou
authors.initials: Z
authors.lastname: Lian
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D045744:Cell Line, Tumor; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D016016:Proportional Hazards Models; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000401:mortality / Q000556:secondary / Q000601:surgery; D012333:RNA, Messenger / Q000235:genetics; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs; D012333:RNA, Messenger; C533097:MIR150, human